Edward Tenthoff
Stock Analyst at Piper Sandler
(3.21)
# 1,112
Out of 5,124 analysts
191
Total ratings
44.2%
Success rate
2.51%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $70 → $100 | $67.79 | +47.51% | 13 | Dec 17, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $28.31 | +58.95% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $72.76 | +71.80% | 5 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $16 → $23 | $10.92 | +110.62% | 6 | Dec 8, 2025 | |
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $30.86 | +104.15% | 13 | Nov 21, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $1.69 | +255.03% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $400.17 | +22.20% | 15 | Oct 31, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $7.19 | +66.90% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $6.00 | +100.00% | 2 | Sep 15, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $13.19 | +13.72% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $53.77 | +95.28% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $10.96 | +82.48% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.34 | +422.39% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $11.47 | +22.06% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.99 | +101.03% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $18.50 | +159.46% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $18.16 | +32.16% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $21.51 | +262.62% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $14.92 | +101.07% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $2.95 | +2,103.39% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.88 | +2,177.39% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.27 | +136.22% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.34 | +789.15% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $15.31 | +4.51% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $0.99 | +508.27% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.05 | +143.90% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $31.85 | +678.65% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.88 | +2,219.59% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $15.15 | +1,088.12% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.17 | +156.26% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $6.68 | +453.89% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $9.39 | +124,830,570.93% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $839.99 | -57.86% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.17 | +11,438.46% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $452.13 | -28.56% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.28 | +143.19% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $43.58 | -17.39% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.54 | +1,523.38% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.62 | +24,093.55% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.49 | +2,835,904.93% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $776.31 | - | 11 | Feb 13, 2017 |
Arrowhead Pharmaceuticals
Dec 17, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $67.79
Upside: +47.51%
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $28.31
Upside: +58.95%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $72.76
Upside: +71.80%
Fulcrum Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $10.92
Upside: +110.62%
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $30.86
Upside: +104.15%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.69
Upside: +255.03%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $400.17
Upside: +22.20%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $7.19
Upside: +66.90%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $6.00
Upside: +100.00%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $13.19
Upside: +13.72%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $53.77
Upside: +95.28%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $10.96
Upside: +82.48%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.34
Upside: +422.39%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $11.47
Upside: +22.06%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.99
Upside: +101.03%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $18.50
Upside: +159.46%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $18.16
Upside: +32.16%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $21.51
Upside: +262.62%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $14.92
Upside: +101.07%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $2.95
Upside: +2,103.39%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.88
Upside: +2,177.39%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.27
Upside: +136.22%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.34
Upside: +789.15%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $15.31
Upside: +4.51%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $0.99
Upside: +508.27%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $2.05
Upside: +143.90%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $31.85
Upside: +678.65%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.88
Upside: +2,219.59%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $15.15
Upside: +1,088.12%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.17
Upside: +156.26%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $6.68
Upside: +453.89%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $9.39
Upside: +124,830,570.93%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $839.99
Upside: -57.86%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.17
Upside: +11,438.46%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $452.13
Upside: -28.56%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.28
Upside: +143.19%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $43.58
Upside: -17.39%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.54
Upside: +1,523.38%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.62
Upside: +24,093.55%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.49
Upside: +2,835,904.93%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $776.31
Upside: -